Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CORT 
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CORT (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $134.5
1 Year Target Price $134.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.17% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.35B USD | Price to earnings Ratio 62.13 | 1Y Target Price 134.5 |
Price to earnings Ratio 62.13 | 1Y Target Price 134.5 | ||
Volume (30-day avg) 4 | Beta 0.2 | 52 Weeks Range 33.34 - 117.33 | Updated Date 08/28/2025 |
52 Weeks Range 33.34 - 117.33 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 18.67% | Operating Margin (TTM) 13.72% |
Management Effectiveness
Return on Assets (TTM) 8.36% | Return on Equity (TTM) 21.7% |
Valuation
Trailing PE 62.13 | Forward PE 86.21 | Enterprise Value 6996670762 | Price to Sales(TTM) 10.26 |
Enterprise Value 6996670762 | Price to Sales(TTM) 10.26 | ||
Enterprise Value to Revenue 9.77 | Enterprise Value to EBITDA 67.38 | Shares Outstanding 105372000 | Shares Floating 86874776 |
Shares Outstanding 105372000 | Shares Floating 86874776 | ||
Percent Insiders 11.55 | Percent Institutions 76.02 |
Upturn AI SWOT
Corcept Therapeutics Incorporated
Company Overview
History and Background
Corcept Therapeutics Incorporated was founded in 1998. It focuses on developing drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on developing and commercializing pharmaceutical products. Primarily targets disorders associated with excess cortisol.
- Research and Development: Conducts research and development activities to discover and develop new treatments, particularly related to cortisol modulation.
Leadership and Structure
Joseph K. Belanoff, M.D., is the CEO. The company has a typical corporate structure with departments including R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Korlym (mifepristone): Korlym is used to control high blood sugar levels (hyperglycemia) in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance. Corcept holds a dominant market share in the Cushing's syndrome drug market. Major competitors include Novartis with Signifor and HRA Pharma with Osilodrostat (Isturisa).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It involves significant R&D investment and faces patent expiration challenges.
Positioning
Corcept is positioned as a specialty pharmaceutical company focusing on cortisol modulation, holding a strong position in the treatment of Cushing's syndrome.
Total Addressable Market (TAM)
The Cushing's syndrome market is estimated to be in the hundreds of millions annually. Corcept is strongly positioned within this niche and exploring applications in oncology.
Upturn SWOT Analysis
Strengths
- Market leader in Cushing's syndrome treatment
- Strong intellectual property protection for Korlym
- Specialized focus allows for deep expertise
- Profitable operations
Weaknesses
- High reliance on a single product (Korlym)
- Generic competition risk
- Regulatory hurdles
- Vulnerability to patent challenges
Opportunities
- Expansion into oncology and other indications
- Development of new cortisol modulating drugs
- Strategic partnerships
- International expansion
Threats
- Generic entry for Korlym
- Competition from other pharmaceutical companies
- Unfavorable regulatory changes
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NVS
- SNY
Competitive Landscape
Corcept has a strong position in Cushing's syndrome. Novartis and other companies offer alternative treatments, but Corcept currently holds a significant market share due to Korlym's established efficacy and market presence. Corcept is trying to grow beyond Cushing's with their pipeline.
Growth Trajectory and Initiatives
Historical Growth: Corcept has experienced growth driven by Korlym sales. Growth rate varies year to year and is dependent on market dynamics.
Future Projections: Analyst estimates vary, but generally project continued growth based on pipeline developments and market expansion.
Recent Initiatives: Corcept is actively pursuing clinical trials for its pipeline compounds, particularly in oncology. They are also defending their patents.
Summary
Corcept Therapeutics is a specialized pharmaceutical company with a strong position in the Cushing's syndrome market, primarily driven by Korlym. The company is profitable, but heavily reliant on a single product, making it vulnerable to generic competition and patent challenges. Future growth depends on the success of its pipeline and strategic initiatives, especially in oncology. The company's financial stability allows for reinvestment into new programs, but it must diversify its revenue stream.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2004-04-14 | Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 500 | Website https://www.corcept.com |
Full time employees 500 | Website https://www.corcept.com | ||
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.